Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of VX-147 in Healthy Adults
NCT05955872Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of inaxaplin in focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of VX-147 Test Compared to VX-147 Reference, Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-147 Test Compared to VX-147 Reference and 2 more. Started Jul 2023; status: completed.
02
Drugs
inaxaplin
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05955872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955872.